GlassScriptPhysician profile
Kathryn M Thomas
NPI 1528019692
$3,475.08
in general payments reported to CMS, 2019-2025
21 companies · $1,496 in 2025
The $1,496 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.09 · 2020: $252 · 2021: $207 · 2022: $90.39 · 2023: $236 · 2024: $1,159 · 2025: $1,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,646 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,645.96 |
| Education | $244.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $835.68 | 2019-2025 | Skyrizi, Rinvoq |
| Leo Pharma INC. | $337.62 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $303.46 | 2024 | Vtama |
| Janssen Biotech, INC. | $298.50 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $288.49 | 2020-2025 | Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $237.12 | 2025 | Nemluvio |
| Pfizer INC. | $198.59 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $175.68 | 2023-2025 | Dupixent, Libtayo |
| Amgen INC. | $129.84 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $122.74 | 2024-2025 | |
| Organon LLC | $109.84 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $109.66 | 2019-2025 | |
| Sandoz INC. | $68.69 | 2023-2024 | Hyrimoz |
| Ucb, INC. | $67.54 | 2024 | Bimzelx |
| Incyte Corporation | $46.01 | 2025 | Opzelura |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $44.26 | 2024-2025 | Zoryve |
| Almirall LLC | $42.57 | 2020-2024 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $20.11 | 2024 | Sotyktu |
| Dermira, INC. | $17.34 | 2020 | |
| Verrica Pharmaceuticals INC. | $17.07 | 2025 | Ycanth |
| Phathom Pharmaceuticals, INC. | $4.27 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.